wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q47718879-747B0F92-112D-41E4-8306-9609CE3D83DE
Q47718879-747B0F92-112D-41E4-8306-9609CE3D83DE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47718879-747B0F92-112D-41E4-8306-9609CE3D83DE
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations.
P2860
Q47718879-747B0F92-112D-41E4-8306-9609CE3D83DE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q47718879-747B0F92-112D-41E4-8306-9609CE3D83DE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
6b0903d7f82648d3e0aef7bef737568c50b4f581
P2860
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.